A Novel Process for Developing Fully Human Monoclonal Antibodies - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A Novel Process for Developing Fully Human Monoclonal Antibodies
The authors describe a process for generating high affinity, fully human antibodies in culture. Specially selected splenocytes are incubated with cytokines and low levels of antigen, yielding affinity-matured, class-switched B cells. The fully human, specific antibodies produced by these cells can then be cloned and expressed for further characterization.

Pharmaceutical Technology
pp. s28-s31

14. A. Schedl et al., Nucleic Acids Res. 20, 3073–3077 (1992).

15. A. Schedl et al., Nucleic Acids Res. 21, 4783–4787 (1993).

16. A. Schedl et al., Nature 362, 258–261 (1993).

17. L. M. Weiner, J. Immunother. 29, 1–9 (2006).

18. R. Jefferis, Adv. Exp. Med. Biol. 564, 143–148 (2005).

19. R. Jefferis and J. Lund, Chem. Immunol. 65, 111–128 (1997).

20. M. A. Coccia and P. Brams, J. Immunol. 161, 5772–5780 (1998).

21. S. M. Santini et al., J. Exp. Med. 191, 1777–1788 (2000).

22. J. M. Carballido et al., Nat. Med. 6, 103–106 (2000).

23. R. Carlsson et al., J. Immunol. 148, 1065–1071 (1992).

24. C. Lapenta et al., J. Exp. Med. 198, 361–367 (2003).

25. M. Tary-Lehmann, A. Saxon, and P. V. Lehmann, Immunol. Today 16, 529–533 (1995).

26. A. R. T. Gerritsen et al., High Throughput Bio-Layer Interferometry in Therapeutic Antibody Discovery and Development (ForteBio, 2010), http://www.fortebio.com/documents/Genmab_Screening_Europe_2010.pdf, accessed Oct. 2012.

27. Octet Biosensors Product Insert, "Streptavidin High Binding Capacity Biosensors-Kinetics and Screening Grade," (ForteBio, 2007), http://www.fortebio.com/documents/41-0046-PD_Rev_B_Streptavidin_High_Binding_PI.pdf, accessed Oct. 2012.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here